Capricor Therapeutics (NASDAQ:CAPR) to Announce Q3 2025 Financial Results

SAN DIEGO, CA — October 31, 2025 — Leads & Copy — Capricor Therapeutics (NASDAQ: CAPR) will release its third quarter financial results on Monday, November 10, 2025, after market close. Management will host a webcast and conference call at 4:30 p.m. ET on the same day.

Call details include toll-free access at 1-800-717-1738, international access at 1-646-307-1865, and conference ID 13683. A replay of the webcast will be available on the company’s website.

Capricor Therapeutics is focused on developing cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is in late-stage clinical development for Duchenne muscular dystrophy (DMD). Capricor is also using its StealthX™ platform in preclinical development for vaccinology and targeted delivery of therapeutics.

Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

Source: Capricor Therapeutics

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.